EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CytoMed Therapeutics's enterprise value is $17.53 Mil.
CytoMed Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, CytoMed Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for CytoMed Therapeutics's EV-to-Revenue or its related term are showing as below:
GDTC's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.145 * Ranked among companies with meaningful EV-to-Revenue only.
CytoMed Therapeutics EV-to-Revenue Historical Data
The historical data trend for CytoMed Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytoMed Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, CytoMed Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's EV-to-Revenue falls into.
CytoMed Therapeutics's current Enterprise Value is $17.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CytoMed Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics's share price for today is $2.0672.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of CytoMed Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoMed Therapeutics (CytoMed Therapeutics) Business Description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GDTC has been successfully added to your